Zhejiang Wecome Pharmaceutical Company Limited
SZSE:300878.SZ
23.26 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 69.776 | -19.651 | 73.861 | 96.177 | 199.953 | 87.619 | 115.563 | 120.7 | 195.739 | 58.092 | 178.726 | 111.839 | 183.784 | 131.541 | 169.582 | 199.57 | 132.26 | 150.375 | 165.856 | 183.782 | 122.755 | 187.511 | 153.496 | 150.397 | 150.397 |
| Cost of Revenue
| 33.911 | 21.999 | 51.218 | 47.09 | 102.128 | 76.947 | 40.149 | 34.473 | 106.195 | 45.82 | 57.915 | 26.938 | 88.409 | 70.097 | 39.25 | 50.248 | 44.781 | 44.748 | 44.964 | 47.172 | 34.536 | 48.742 | 39.562 | 39.731 | 39.731 |
| Gross Profit
| 35.865 | -41.65 | 22.643 | 49.088 | 97.825 | 10.673 | 75.414 | 86.227 | 89.544 | 12.273 | 120.811 | 84.901 | 95.376 | 61.444 | 130.332 | 149.322 | 87.479 | 105.627 | 120.892 | 136.61 | 88.219 | 138.769 | 113.934 | 110.666 | 110.666 |
| Gross Profit Ratio
| 0.514 | 2.12 | 0.307 | 0.51 | 0.489 | 0.122 | 0.653 | 0.714 | 0.457 | 0.211 | 0.676 | 0.759 | 0.519 | 0.467 | 0.769 | 0.748 | 0.661 | 0.702 | 0.729 | 0.743 | 0.719 | 0.74 | 0.742 | 0.736 | 0.736 |
| Reseach & Development Expenses
| 2.671 | 2.005 | 5.6 | 3.248 | 2.971 | 22.932 | 3.382 | 7.642 | 8.842 | 11.253 | 10.216 | 10.043 | 7.808 | 21.427 | 6.317 | 5.179 | 4.092 | 7.723 | 5.439 | 1.346 | 5.901 | 5.921 | 5.605 | 4.817 | 4.817 |
| General & Administrative Expenses
| 9.612 | -21.898 | 29.828 | -7.432 | 10.774 | -20.44 | 24.762 | -4.714 | 8.605 | 8.445 | 25.187 | -6.24 | 8.77 | -11.326 | 14.911 | -2.125 | 5.016 | -9.147 | 6.716 | 6.805 | 7.517 | -25.437 | 5.526 | 6.002 | 6.002 |
| Selling & Marketing Expenses
| 30.418 | -36.178 | 101.937 | 53.315 | 52.337 | 84.618 | 39.888 | 43.662 | 40.018 | 38.284 | 48.786 | 36.905 | 57.063 | 43.123 | 81.563 | 90.671 | 54.632 | 56.611 | 73.927 | 82.327 | 55.215 | 75.26 | 75.153 | 70.692 | 70.692 |
| SG&A
| 40.03 | -58.076 | 131.765 | 58.325 | 63.111 | 64.179 | 64.65 | 38.948 | 48.623 | 67.884 | 73.973 | 30.665 | 65.833 | 31.797 | 96.474 | 88.546 | 59.648 | 47.464 | 80.643 | 89.132 | 62.731 | 49.823 | 80.679 | 77.601 | 77.601 |
| Other Expenses
| -5.409 | 216.225 | -149.215 | -0.058 | -0.283 | 0.336 | -4.579 | -0.122 | -0.407 | -18.821 | -0.053 | -0.047 | 0.093 | -0.027 | 3.028 | -2.223 | 0.108 | -5.131 | 0.369 | 0.013 | -0.897 | 0.445 | 0.057 | 0 | 0 |
| Operating Expenses
| 37.292 | 160.154 | -11.85 | 61.63 | 68.629 | 116.339 | 51.521 | 60.195 | 56.405 | 60.316 | 72.158 | 43.5 | 73.521 | 72.117 | 95.117 | 93.736 | 63.332 | 55.814 | 82.36 | 82.49 | 68.841 | 86.708 | 84.678 | 77.048 | 77.048 |
| Operating Income
| -1.427 | -201.805 | 34.494 | -12.542 | 26.634 | -95.21 | 20.303 | 40.854 | 33.039 | -48.043 | 46.844 | 39.84 | 26.209 | -11.098 | 36.464 | 50.09 | 23.686 | 51.721 | 37.777 | 50.505 | 19.036 | 50.832 | 29.389 | 33.699 | 33.699 |
| Operating Income Ratio
| -0.02 | 10.269 | 0.467 | -0.13 | 0.133 | -1.087 | 0.176 | 0.338 | 0.169 | -0.827 | 0.262 | 0.356 | 0.143 | -0.084 | 0.215 | 0.251 | 0.179 | 0.344 | 0.228 | 0.275 | 0.155 | 0.271 | 0.191 | 0.224 | 0.224 |
| Total Other Income Expenses Net
| -0.791 | -0.3 | -6.763 | 2.289 | -0.283 | 0.336 | -4.579 | -0.122 | -0.407 | -1.694 | -0.053 | -0.047 | 0.093 | -0.027 | 0.436 | 0.369 | 0.108 | 0.178 | 0.369 | 0.013 | -0.897 | 0.499 | 0.057 | -0.268 | -0.268 |
| Income Before Tax
| -2.217 | -202.104 | 27.73 | -10.253 | 26.351 | -94.874 | 15.725 | 40.732 | 32.632 | -49.737 | 46.791 | 39.794 | 26.302 | -11.125 | 36.9 | 50.459 | 23.794 | 51.898 | 38.146 | 50.518 | 18.14 | 51.331 | 29.446 | 33.431 | 33.431 |
| Income Before Tax Ratio
| -0.032 | 10.285 | 0.375 | -0.107 | 0.132 | -1.083 | 0.136 | 0.337 | 0.167 | -0.856 | 0.262 | 0.356 | 0.143 | -0.085 | 0.218 | 0.253 | 0.18 | 0.345 | 0.23 | 0.275 | 0.148 | 0.274 | 0.192 | 0.222 | 0.222 |
| Income Tax Expense
| 7.489 | -11.021 | -2.494 | -1.844 | 1.962 | -17.817 | 10.377 | 3.224 | 4.614 | 4.576 | 9.669 | 5.401 | 3.173 | -14.906 | 7.687 | 7.278 | 3.422 | 5.491 | 6.893 | 8.205 | 2.407 | 8.86 | 2.871 | 4.948 | 4.948 |
| Net Income
| -9.855 | -191.524 | 29.905 | -10.143 | 24.335 | -77.389 | 4.73 | 37.095 | 27.526 | -45.121 | 36.945 | 34.066 | 22.92 | 3.777 | 28.947 | 43.498 | 20.273 | 46.518 | 31.253 | 42.313 | 15.732 | 42.472 | 26.575 | 28.483 | 28.483 |
| Net Income Ratio
| -0.141 | 9.746 | 0.405 | -0.105 | 0.122 | -0.883 | 0.041 | 0.307 | 0.141 | -0.777 | 0.207 | 0.305 | 0.125 | 0.029 | 0.171 | 0.218 | 0.153 | 0.309 | 0.188 | 0.23 | 0.128 | 0.227 | 0.173 | 0.189 | 0.189 |
| EPS
| -0.07 | -1.343 | 0.21 | -0.071 | 0.17 | -0.63 | 0.033 | 0.26 | 0.19 | -0.32 | 0.26 | 0.24 | 0.28 | 0.027 | 0.36 | 0.65 | 0.14 | 0.98 | 0.22 | 0.39 | 0.14 | 0.39 | 0.24 | 0.26 | 0.26 |
| EPS Diluted
| -0.07 | -1.343 | 0.21 | -0.071 | 0.17 | -0.63 | 0.033 | 0.26 | 0.19 | -0.32 | 0.26 | 0.24 | 0.28 | 0.027 | 0.36 | 0.65 | 0.14 | 0.98 | 0.22 | 0.39 | 0.14 | 0.39 | 0.24 | 0.26 | 0.26 |
| EBITDA
| -0.282 | -196.969 | 28.758 | 6.323 | 42.229 | -79.284 | 29.843 | 56.022 | 46.546 | -55.046 | 64.818 | 49.578 | 35.949 | 1.539 | 47.477 | 47.472 | 28.244 | 51.902 | 38.261 | 53.313 | 21.614 | 51.388 | 30.959 | 35.256 | 35.256 |
| EBITDA Ratio
| -0.004 | 10.023 | 0.389 | 0.066 | 0.211 | -0.905 | 0.258 | 0.464 | 0.238 | -0.948 | 0.363 | 0.443 | 0.196 | 0.012 | 0.28 | 0.238 | 0.214 | 0.345 | 0.231 | 0.29 | 0.176 | 0.274 | 0.202 | 0.234 | 0.234 |